Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus semaglutide plus SGLT2 inhibitor in type 2 diabetes mellitus with MAFLD
ChiCTR2600134083Phase 4Completed
- Sponsor
- Xiamen Humanity Hospital
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Xiamen Humanity Hospital. Primary endpoints: Degree of fatty liver at 52 weeks, Free fatty acids in blood and 1 more. Started May 2025; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2600134083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134083.